Rejuvenated Hematopoietic Stem and Progenitor Cell-Engineered CAR-Armored Natural Killer T Cells for Malignant Pleural Mesothelioma - PubMed
6 hours ago
- #CAR-NKT cells
- #Mesothelioma therapy
- #Allogeneic immunotherapy
- The study develops allogeneic interleukin-15-augmented, mesothelin-specific CAR-armored natural killer T (Allo15MCAR-NKT) cells for treating malignant pleural mesothelioma (MPM).
- These cells are engineered from hematopoietic stem and progenitor cells, enabling scalable production with high yield and purity, and show robust antitumor efficacy in vitro and in vivo MPM models.
- Allo15MCAR-NKT cells modulate the tumor microenvironment by targeting CD1d+ tumor-associated macrophages and exhibit a rejuvenated profile with low exhaustion markers, indicating sustained function.
- The therapy demonstrates a favorable safety profile with minimal risks of graft-versus-host disease, cytokine release syndrome, neurotoxicity, or off-tumor effects, supporting its potential as an off-the-shelf treatment.